PI
CHRS icon

Pennant Investors’s Coherus Oncology CHRS Stock Holding History

Pennant Investors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-168,100
Closed -$291K – 25
2024
Q2 		$291K Hold
168,100
– – 0.08% 32
2024
Q1 		$402K Hold
168,100
– – 0.1% 30
2023
Q4 		$560K Buy
+168,100
New +$450K 0.12% 15

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pennant Investors's CHRS Position: Q3 2024 in Review

Pennant Investors sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 168,100 shares — an estimated $291K sold.

Pennant Investors first reported a position in CHRS in Q4 2023 and held it in 3 quarters. The position peaked at $560K in Q4 2023. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Pennant Investors reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 168,100 Coherus Oncology shares in Q3 2024, an estimated $291K.
  • Pennant Investors first reported a position in Coherus Oncology in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Coherus Oncology position peaked at $560K in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.